

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DE SANTIS, Rita

Atty. Ref.:

Serial No. unknown

Group:

Filed: October 18, 2001

Examiner:

For: ANTIGEN PRESENTING CELLS, METHOD FOR THEIR PREPARATION AND
THEIR USE FOR CANCER VACCINES

* * * * *

October 18, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

IN THE CLAIMS

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

099439-101801
TOTAL 62.8660

5. A method according to claim 1, wherein said cells are immune cells.
6. A method according to claim 1, wherein said cells are non-immune cells.
7. A method according to claim 1, wherein said cells express shared immunodominant cancer antigens.
8. A method according to claim 1, wherein said cells are express shared not immunodominant cancer antigens.
9. A method according to claim 1, wherein said cells are Epstein-Barr virus-immortalized B-lymphoblastoid cell lines.
10. A method according to claim 1, wherein said cells are Pokeweed mitogen (PWM)-activated B-lymphocytes.
11. A method according to claim 1, wherein said cells are CD40 activated B-lymphocytes.
12. A method according to claim 1, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2)-activated PBMC.
13. A method according to claim 1, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2) + pokeweed mitogen (PWM)-activated PBMC.
14. A method according to claim 1, wherein said cells are dendritic cells, monocytes, macrophages.
15. A method according to claim 1, wherein said cells are CD34+ cells, fibroblasts, stem cells, fibroblasts and cheratinocytes.

16. A method according to claim 1, wherein histone deacetylase inhibitors are used in step d).
17. A method according to claim 1, wherein said DNA hypomethylating agent is selected from 5-aza-cytidine or 5-aza-2'-deoxycytidine.
18. Cells obtainable by the method according to claim 1.
23. Use according to claim 19, wherein said cells are stored as reservoir of pooled antigens.
28. Vaccine according to claim 27, wherein the cells are used.
29. Vaccine according to claim 27, wherein cellular components are used.
31. An article of manufacture comprising a vaccine according to claim 25 and a pharmaceutical composition suitable for systemic administration of a hypomethylating agent.

Error! Reference source not found.
Serial No. unknown


REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page/s is/are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Arthur R. Crawford
Reg. No.25,327

ARC:ecb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

09031239.101801
T.D370T.6E2T8660

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

5. A method according to ~~any of claims 1-4~~, wherein said cells are immune cells.
6. A method according to ~~any of claims 1-4~~, wherein said cells are non-immune cells.
7. A method according to ~~any of claims 1-6~~, wherein said cells express shared immunodominant cancer antigens.
8. A method according to ~~any of claims 1-6~~, wherein said cells are express shared not immunodominant cancer antigens.
9. A method according to ~~any of claims 1-5 and any of claims 7-8~~, wherein said cells are Epstein-Barr virus-immortalized B-lymphoblastoid cell lines.
10. A method according to ~~any of claims 1-5 and any of claims 7-8~~, wherein said cells are Pokeweed mitogen (PWM)-activated B-lymphocytes.
11. A method according to ~~any of claims 1-5 and any of claims 7-8~~, wherein said cells are CD40 activated B-lymphocytes.
12. A method according to ~~any of claims 1-5 and any of claims 7-8~~, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2)-activated PBMC.
13. A method according to ~~any of claims 1-5 and any of claims 7-8~~, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2) + pokeweed mitogen (PWM)-activated PBMC.

14. A method according to ~~any of claims 1-4 and any of claims 6-8~~, wherein said cells are dendritic cells, monocytes, macrophages.

15. A method according to ~~any of claims 1-4 and any of claims 6-8~~, wherein said cells are CD34+ cells, fibroblasts, stem cells, fibroblasts and cheratinocytes.

16. A method according to ~~any of claims 1-15~~, wherein histone deacetylase inhibitors are used in step d).

17. A method according to ~~any of claim 1-16~~, wherein said DNA hypomethylating agent is selected from 5-aza-cytidine or 5-aza-2'-deoxycytidine.

18. Cells obtainable by the method according to ~~any one of claims 1-17~~.

23. Use according to ~~any of claims 19-22~~, wherein said cells are stored as reservoir of pooled antigens.

28. Vaccine according to claim 27, wherein the cells are used ~~as according to claim 23~~.

29. Vaccine according to claim 27 ~~or 28~~, wherein cellular components ~~according to claim 19~~ are used.

31. An article of manufacture comprising a vaccine according to ~~any of claims 25-29~~ and a pharmaceutical composition suitable for systemic administration of a hypomethylating agent.